These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 25847403)

  • 21. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
    Zoutendijk R; Reijnders JG; Zoulim F; Brown A; Mutimer DJ; Deterding K; Hofmann WP; Petersen J; Fasano M; Buti M; Berg T; Hansen BE; Sonneveld MJ; Wedemeyer H; Janssen HL;
    Gut; 2013 May; 62(5):760-5. PubMed ID: 22490523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of interferon-based therapy for chronic hepatitis C.
    Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
    Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
    Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
    Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
    Ueno Y; Sollano JD; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001.
    Giordano TP; Kramer JR; Souchek J; Richardson P; El-Serag HB
    Arch Intern Med; 2004 Nov; 164(21):2349-54. PubMed ID: 15557414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
    Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
    Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
    Zheng YX; Zhou PC; Zhou RR; Fan XG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):759-766. PubMed ID: 28240613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver fibrosis progression in hepatitis C virus infection after seroconversion.
    Butt AA; Yan P; Lo Re V; Rimland D; Goetz MB; Leaf D; Freiberg MS; Klein MB; Justice AC; Sherman KE;
    JAMA Intern Med; 2015 Feb; 175(2):178-85. PubMed ID: 25485735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model.
    Ikeda K; Kawamura Y; Kobayashi M; Fukushima T; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2014; 86(5-6):295-302. PubMed ID: 24924385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
    Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
    Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
    Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
    Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    Am J Gastroenterol; 2014 Sep; 109(9):1427-35. PubMed ID: 25070058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.